Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.7% surge in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite this, the stock underperformed its sector and closed marginally lower, raising questions about the directional bets underpinning this spike in open interest.

Surging to a fresh 52-week and all-time high of Rs 1739 on 21 Sep 2026, Aurobindo Pharma Ltd. has demonstrated remarkable price momentum, outperforming the broader market by a significant margin over the past year. This milestone caps a 54.49% rally from its 52-week low of Rs 1066, underscoring the stock’s sustained technical strength amid a mixed market backdrop.

Surging past its previous peaks, Aurobindo Pharma Ltd. reached a new 52-week high of Rs 1707.9 on 18 Sep 2026, marking a remarkable 53.7% gain over the past year. This rally stands in stark contrast to the broader market, with the Sensex down 10.5% over the same period, underscoring the stock’s strong momentum despite a challenging environment.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 15 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 September 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Aurobindo Pharma Ltd. has witnessed a significant 21.6% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock underperformed its sector and traded in a narrow range close to its 52-week high, reflecting a complex interplay of bullish and cautious sentiments among traders.

With a remarkable 64.8% gain over the past year, Aurobindo Pharma Ltd. surged to a fresh 52-week high of Rs 1706.7 on 1 Sep 2026, outpacing the Sensex which declined by 4.2% over the same period. This milestone underscores the stock’s sustained momentum amid a broader market that has been under pressure.

Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, coinciding with robust price gains and sustained bullish momentum. The pharmaceutical giant’s stock hit a fresh 52-week high of Rs 1,684.7 on 31 Aug 2026, supported by a 13.3% increase in open interest, signalling heightened market participation and potential directional bets by traders.

Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent price action, combined with rising volumes and open interest, suggests a strengthening bullish sentiment despite some cautionary signs from delivery volumes and investor participation.

Surging past its previous peaks, Aurobindo Pharma Ltd. reached a fresh 52-week high of Rs 1692 on 31 Aug 2026, marking a remarkable 64.4% gain over the past year. This milestone comes amid a backdrop of sustained technical momentum, even as the broader market struggles to maintain its footing.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 24 August 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 11.06% increase in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite this surge, the stock has underperformed its sector and broader indices, reflecting a complex interplay of bullish and bearish sentiments among traders.

Aurobindo Pharma Ltd. has witnessed a notable 10.18% increase in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite this surge, the stock has underperformed its sector and the broader Sensex over the past two days, reflecting a complex interplay between bullish bets and short-term price pressures.

Surging past its previous peaks, Aurobindo Pharma Ltd. reached a fresh 52-week high of Rs 1682 on 13 Aug 2026, marking a remarkable 55.22% gain over the past year. This rally stands in stark contrast to the Sensex’s decline of 3.47% over the same period, underscoring the stock’s strong momentum despite broader market headwinds.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging to a new 52-week and all-time high of Rs 1671.3 on 10 Aug 2026, Aurobindo Pharma Ltd. has demonstrated remarkable price momentum, outperforming the Sensex by nearly 61 percentage points over the past year. This milestone caps a sustained rally that has seen the stock climb from its 52-week low of Rs 1017, underscoring a strong technical backdrop that continues to support the uptrend despite a modest underperformance on the day.

Surging past its previous peaks, Aurobindo Pharma Ltd. touched a fresh 52-week high of Rs 1638.8 on 7 Aug 2026, marking a remarkable 52.7% gain over the past year. This milestone comes amid a backdrop of strong technical momentum that has propelled the stock well above its key moving averages, even as the broader Sensex trades lower.